Predicting study duration in clinical trials with a time-to-event endpoint

被引:2
|
作者
Machida, Ryunosuke [1 ,2 ]
Fujii, Yosuke [3 ]
Sozu, Takashi [4 ]
机构
[1] Tokyo Univ Sci, Dept Informat & Comp Technol, Grad Sch Engn, Tokyo, Japan
[2] Natl Canc Ctr, Ctr Res Adm & Support, Biostat Div, Tokyo, Japan
[3] Pfizer R&D Japan GK, Biometr & Data Management, Tokyo, Japan
[4] Tokyo Univ Sci, Fac Engn, Dept Informat & Comp Technol, Tokyo, Japan
基金
日本学术振兴会;
关键词
clinical trial; prediction; sample size; study duration; time‐ to‐ event; FOLLOW-UP; SURVIVAL; RECRUITMENT; ENROLLMENT; COUNTS;
D O I
10.1002/sim.8911
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In event-driven clinical trials comparing the survival functions of two groups, the number of events required to achieve the desired power is usually calculated using the Freedman formula or the Schoenfeld formula. Then, the sample size and the study duration derived from the required number of events are considered; however, their combination is not uniquely determined. In practice, various combinations are examined considering the enrollment speed, study duration, and the cost of enrollment. However, effective methods for visually representing their relationships and evaluating the uncertainty in study duration are insufficient. We developed a graphical approach for examining the relationship between sample size and study duration. To evaluate the uncertainty in study duration under a given sample size, we also derived the probability density function of the study duration and a method for updating the probability density function according to the observed number of events (ie, information time). The proposed methods are expected to improve the operation and management of clinical trials with a time-to-event endpoint.
引用
收藏
页码:2413 / 2421
页数:9
相关论文
共 50 条
  • [1] Milestone prediction for time-to-event endpoint monitoring in clinical trials
    Ou, Fang-Shu
    Heller, Martin
    Shi, Qian
    PHARMACEUTICAL STATISTICS, 2019, 18 (04) : 433 - 446
  • [2] Consideration of stratification in confirmatory trials with time-to-event endpoint
    Wang, Yizhuo
    Zhou, Xuan
    Guo, Zifang
    Fang, Xiao
    Liu, Fang
    Shen, Liji
    CONTEMPORARY CLINICAL TRIALS, 2024, 141
  • [3] A hybrid approach to predicting events in clinical trials with time-to-event outcomes
    Fang, Liang
    Su, Zheng
    CONTEMPORARY CLINICAL TRIALS, 2011, 32 (05) : 755 - 759
  • [4] A Bayesian adaptive design for biosimilar trials with time-to-event endpoint
    Belay, Sheferaw Y.
    Mu, Rongji
    Xu, Jin
    PHARMACEUTICAL STATISTICS, 2021, 20 (03) : 597 - 609
  • [5] Predicting events in clinical trials using two time-to-event outcomes
    Mu, Rongji
    Xu, Jin
    BIOMETRICAL JOURNAL, 2018, 60 (04) : 815 - 826
  • [6] Analysis of time-to-event and duration outcomes in neonatal clinical trials with twin births
    Shaffer, Michele L.
    Hiriote, Sasiprapa
    CONTEMPORARY CLINICAL TRIALS, 2009, 30 (02) : 150 - 154
  • [7] Group sequential testing for cluster randomized trials with time-to-event endpoint
    Li, Jianghao
    Jung, Sin-Ho
    BIOMETRICS, 2022, 78 (04) : 1353 - 1364
  • [8] Sample size calculation for cluster randomization trials with a time-to-event endpoint
    Li, Jianghao
    Jung, Sin-Ho
    STATISTICS IN MEDICINE, 2020, 39 (25) : 3608 - 3623
  • [9] Development of a time-to-event endpoint for use in premanifest Huntington's disease (HD) clinical trials
    Rossomanno, S.
    Guthrie, H.
    Wild, E. J.
    Schobel, S. A.
    Boak, L.
    Trundell, D.
    MOVEMENT DISORDERS, 2020, 35 : S102 - S102
  • [10] Comparison of Time-to-Event Data for Clinical Trials
    Nadarajah, Saralees
    MONTE CARLO METHODS AND APPLICATIONS, 2007, 13 (01): : 21 - 35